about
The Clinical Relevance of Age at Presentation in NephroblastomaBiology and treatment of renal tumours in childhoodAmplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumorsLin28 sustains early renal progenitors and induces Wilms tumorHuman Tissue and ‘the Public’: The Case of Childhood Cancer Tumour BankingFrequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor.Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature.Effect of media portrayals of removal of children's tissue on UK tumour bank.Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.Listening to patients with cancer: using a literary-based research method to understand patient-focused careDeclining childhood and adolescent cancer mortality: great progress but still much to be done.miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema.Role for amplification and expression of glypican-5 in rhabdomyosarcoma.Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood.Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumourThe yin and yang of kidney development and Wilms' tumorsMultiple mechanisms of MYCN dysregulation in Wilms tumour.A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome.Stratification of Wilms tumor by genetic and epigenetic analysisClinical features of molecular pathology of solid tumours in childhood.Consent for childhood cancer tissue banking in the UK: the effect of the Human Tissue Act 2004.Evidence for a delay in diagnosis of Wilms' tumour in the UK compared with Germany: implications for primary care for children.Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups.Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analogIntra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications.Study protocol for a randomised controlled trial of brief, habit-based, lifestyle advice for cancer survivors: exploring behavioural outcomes for the Advancing Survivorship Cancer Outcomes Trial (ASCOT).Nephrectomy-only for Wilms tumour: negotiating the tangled web requires multi-professional input.Management of adults with Wilms' tumor: recommendations based on international consensus.An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour.New policies to address the global burden of childhood cancers.Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA.Biomarkers to detect Wilms tumors in pediatric patients: where are we now?Bilateral Wilms tumour: a review of clinical and molecular features.Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: The UK SIOP Wilms Tumor 2001 Trial experience.Ethical issues of clinical trials in paediatric oncology from 2003 to 2013: a systematic review.Wilms tumor: "State-of-the-art" update, 2016.Review of phase I and II trials for Wilms' tumour - Can we optimise the search for novel agents?
P50
Q28072280-02250A83-3190-436A-BCE0-A832C3076AC8Q28074627-D89F0AFF-8787-4EC1-A02C-26845C225BA8Q28280617-9F4947B7-570D-4E4B-9721-A982910F30FEQ28511047-04BC99D1-1A5B-4680-9D8F-8A4FFEEE65A8Q28816171-42832FF9-6444-4774-87F0-BDB1BECE669AQ30945124-C87E45C9-750B-42F8-B8E7-A944D67BECF2Q33195114-28A6F1C9-8287-418D-9E66-E203E7DF9C9DQ33449035-734F8CF3-9337-46C4-BDC4-F305295CADA0Q33893718-B3BF4706-3693-4F2D-A4B5-190B8A723AA6Q34338441-7459C111-021D-48DF-8D58-34ED281FC91DQ34365095-C6A09E05-CF92-40D4-9638-34E58795856AQ34511492-DBDAD374-0C79-4932-9D3A-599F1AD6D1E8Q34545051-69C9A2A1-70D0-4C32-B2B3-C1000F9D81C5Q34599459-0B1F5A32-5744-402D-9FFB-8304FC18C61AQ34949192-3BA3B772-39B8-4B09-B83A-720AD7923F75Q35005638-963B6FCE-D5D1-451A-9E04-D2F337D859F6Q35027111-70541622-3408-410C-A115-44BC06C788FDQ35163343-41EE1B7E-1845-4D5C-B6E0-8085CCBABFB7Q35173260-7C3D9C4B-8212-46CB-8A5B-75EF5B6D608BQ35740193-D0346F74-7011-4910-A880-6978E25F23EEQ35926983-1580C81C-04BB-469E-9955-AE0D01070AB8Q35987087-25D39C24-AFA6-4669-BF58-27CBCAC6AF52Q36145215-EF71874B-9960-471A-9C79-A3CED5E017B4Q36747701-25D89FB1-C1C7-4B0F-8330-B7D41B9C54FDQ36886687-1859E6DE-C6D0-4943-94A1-E3A320E69FFCQ37038669-B5AFC760-FC1E-4315-ABEE-93726FA3A2BFQ37098271-6AA3109D-B4CD-40DA-BF3C-B4A157A81D0EQ37149909-B8FEA55B-8909-4509-AD2A-1E59F94D2DE5Q37527138-8CBEF42C-0702-4BF2-8A2C-9FC2C84C1F0BQ37734335-C17AEF47-AB76-4EEE-8FC7-8A6E722E911AQ37909371-9B08C8F4-C45D-4802-8845-6DD4E1B26F2EQ38041750-BB0C68C3-7B49-4AB4-98C0-186CFBFE591EQ38084015-EF61D985-686C-495B-B798-6CB329AEC1AAQ38440321-0D52674B-FEF0-4BFD-8C87-F5CB6B536EA7Q38559338-12352053-83A1-49D1-945D-CE573088420FQ38675275-EDCA9180-ECB1-44F6-A0E8-EB6959826377Q38850325-61D82083-A1EA-40DD-A77D-1DA3B5BE06C8Q38865001-5CABD84E-A451-4A27-943D-4D9BFCD24E9BQ39036543-322207D4-895B-415A-A415-25F256996EE6Q39315849-8F96CF36-5D24-41A6-9E4A-0BAC123120CB
P50
name
Kathy Pritchard-Jones
@ast
Kathy Pritchard-Jones
@en
Kathy Pritchard-Jones
@nl
type
label
Kathy Pritchard-Jones
@ast
Kathy Pritchard-Jones
@en
Kathy Pritchard-Jones
@nl
prefLabel
Kathy Pritchard-Jones
@ast
Kathy Pritchard-Jones
@en
Kathy Pritchard-Jones
@nl